Diabetes Obesity & Metabolism

Article	Citations
Diabetes, Obesity and Metabolism	835
	325
Issue Information	272
Front Cover	211
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic	203
SemaGBA : A System Dynamics Model of the Semaglutide‐Responsive Gut‐Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight	158
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study	139
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy	129
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”	115
Involvement of the FTO A > T polymorphism in body composition and lipid profile changes after aerobic training in adults with overweight and obesity	112
Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’	102
Spillover effects of a nudge‐based dietary intervention on physical activity and sleep among adults with type 2 diabetes: Evidence from a randomised controlled trial	99
Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials	96
Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover	96
Pathway‐Specific Polygenic Risk Scores and Cardiorenal Complications in Asians With Type 2 Diabetes	92
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic	90
Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta‐analysis	89
Long‐term effects of metformin on offspring health: A review of current evidence and future directions	88
Global, regional and country‐specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study	83
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes	83
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors	80
Newly defined clinical obesity versus body mass index ‐defined obesity: Differential risks of overall death and adverse events in a population‐based	72
Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of Italy	71
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis	71
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial	68

Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study	67
Effects of CB1R inverse agonist, INV ‐202, in patients with features of metabolic syndrome. A rand	66
The lifetime health and economic burden of obesity in five European countries: what is the potential impact of prevention?	65
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial	65
Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide	64
Maternal Pregestational and Gestational Diabetes and Neuropsychiatric Risk in Offspring: A Binational Cohort Study	63
The effects of antihypertensive drugs on glucose metabolism	60
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry	59
Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020	59
Effects of GLP ‐1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta‐analysis based on randomized	56
Development of the health economic model for type 2 diabetes considering glycaemic variability	56
Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabet	53
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease	53
Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in typ	53
Glycaemic Outcomes of a Novel Model‐Predictive‐Control‐Based Hybrid Closed‐Loop System in Chinese Adolescents and Adults With Type 1 Diabetes: A Multicentre Pivotal Trial	52
Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009–2019	52
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study	50
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia	50
CHIP mediates glucagon action on hepatic glucose production via regulating Smad3 ubiquitination	48
Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice	47
Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada	47
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’	47
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin	46
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta‐analysis	46
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐bli	46
Adaptive bolus calculators for people with type 1 diabetes: A systematic review	45
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes	45
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes	45
Plasma fatty acid esters of hydroxy fatty acids and surrogate fatty acid esters of hydroxy fatty acids hydrolysis activity in children with or without obesity and in adults with or without coronary ar	43
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes	42
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Coh	42
Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis	42
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status	42
Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity	41
Serum levels of the incretin‐like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Resul	41
Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study	41
Continuous glucose monitoring and all‐cause mortality in insulin‐using population with diabetes and cognitive impairment	41
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial	40
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial	39
Identifying Predictors of Early Treatment Intensification in Individuals With Type 2 Diabetes Treated With GLP ‐1 Receptor Agonists: A Machine Learni	39
Incidence of chronic kidney disease among adults with prediabetes in the CURE ‐ CKD registry, 2013	39
Higher post‐prandial glucose excursions in youth with type 1 diabetes and celiac disease: Time to change the bolus?	39
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis	38
GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity	38
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pum	38
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c	38
Effect of saroglitazar on glycaemic parameters: A systematic review and meta‐analysis of randomized controlled trials	37
Safety and efficacy of an oral insulin ( Capsulin ) in patients with early‐stage type 2 diabetes: A dose‐ranging phase 2b	37
Five‐year trajectories of HbA1c by age, sex, ethnicity and deprivation in adults with newly diagnosed type 2 diabetes: Observational study in England	37
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme	37

Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral Nutrients in Type 2 Diabetes	37
Diabetic distal symmetric polyneuropathy: More than just “tingling in the feet”	36
Nomogram model and risk score to predict 5‐year risk of progression from prediabetes to diabetes in Chinese adults: Development and validation of a novel model	36
Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases	35
Beta cell function and global glucose metabolism are impaired in Dp(16)1Yey mouse model of Down syndrome	35
Healthy lifestyle and all‐cause and cause‐specific dementia in individuals with type 2 diabetes and the roles of diabetes duration and insulin use in UK	35
	35
Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor	35
Diabetes, Obesity and Metabolism	34
Issue Information	34
Issue Information	34
Interrupting prolonged sitting reduces postprandial GIP but not GLP ‐1 responses in type 2 diabete	34
Front Cover	34
Efficacy and safety of DBPR108 (prusogliptin) as an add‐on to metformin therapy in patients with type 2 diabetes: A 24‐week, multi‐centre, randomized	34
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in h	33
Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of	33
Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico	33
Development and validation of a novel method for evaluation of multiple islet autoantibodies in dried blood spot using dissociation‐enhanced lanthanide fluorescent immunoassays technology, specific an	33
Correction to “Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of a	33
Diabetes and incident stroke and mediation by microvascular dysfunction: Pooled analysis of three population‐based studies	33
Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study	33
Comments on ‘Propensity score matching methodology in Riley et al.'s study on type 2 diabetes and obstructive sleep apnoea’	32
Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes	32
Obesity and overweight‐related differences in cardiometabolic risk factors in type 1 diabetes	32
Comparative efficacy of sleeve gastrectomy with fundoplication versus standard sleeve gastrectomy in obesity and gastroesophageal reflux disease: A randomised trial	32
Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin–activin–follistatin– IGF ‐1 axis: R	32
Positive allosteric γ‐aminobutyric acid type A receptor modulation prevents lipotoxicity‐induced injury in hepatocytes in vitro	32
Effects of reducing sedentary behaviour on renal glucose uptake during insulin stimulation: A post‐hoc analysis of a 6‐month randomized controlled trial	32
Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomise	32
Effect of renin‐angiotensin system antihypertensive medication use on cognitive function in diabetes mellitus with obesity or overweight: An ancillary study to the Action for Health in Diabetes (Look	32
Efficacy and safety of intragastric expandable oral capsules in adults with overweight or obesity: A randomized, double‐blind, placebo‐controlled trial	31
Is composite cardiovascular death or hospitalization for heart failure a valid surrogate for mortality in patients treated with sodium‐glucose cotransporter 2 inhibitors? A correlation meta‐analysis	31
Impaired awareness of hypoglycaemia: Prevalence and associated factors before and after FreeStyle L ibre use in the Associat	31
Exploring new frontiers: Effects of psychedelics on neurotransmitter‐regulated glucagon release in pancreatic islets	31
Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study	31
Weight change in patients with new‐onset type 2 diabetes mellitus and its association with remission: Comprehensive real‐world data	31
Current insulin infusion set failure criteria may be too stringent for real‐life settings and may skew infusion set failure outcomes in extended‐wear infusion set studies	31
Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure	30
Future diabetes risk can be predicted by the number of abnormal oral glucose tolerance test values during pregnancy	30
Post‐semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system	30
Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre	30
Effects of intensive treatment of Chinese women with gestational diabetes on the risk of offspring being overweight from 3 to 8 years of age	30
Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in Taiwan	30
Risk of depression with GLP ‐1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new‐user, active‐comparator cohort study	30
Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on empagliflozin (Empa‐AA): Insights from real‐	30
Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes	30
Mechanism of Terpinen‐4‐ol in Suppressing β‐Cell Dedifferentiation: Restoring Mitophagy and Alleviating Mitochondrial Calcium Overload via Parkin‐Med	30
Accelerated onset of diabetes in non‐obese diabetic mice fed a refined high‐fat diet	30
Glycated haemoglobin, HOMA2‐B , C‐peptide to glucose ratio and type 2 diabetes clusters as predict	30
The 1‐Hour Plasma Glucose for Early Risk Stratification in Young, Obese Chinese Adults: Implications for Clinical Management	29
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study	29
Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK : A long‐term cost‐effectiveness analysis based on	29
Early versus late initiation of long‐acting insulin in paediatric and adult diabetic ketoacidosis: A systematic review and meta‐analysis of randomised control trials	29
Generating real‐world evidence on diabetes technology using the CareLink Personal data management system	29
Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysi	29
Associations of metformin and sulfonylurea on vascular complications in early‐ and late‐onset type 2 diabetes: A cohort study	29
Long‐term delirium and survival outcomes in patients treated with GLP ‐1 receptor agonists versus metformin in type 2 diabetes: A population‐based co	29
The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021	28
Postnatal glycaemic outcomes in women with high‐risk gestational diabetes: Identifying key predictors for early intervention	28
The depletion of serine beta‐lactamase‐like protein (LACTB) ameliorates metabolic dysfunction–associated steatotic liver disease by reducing ubiquitin‐mediated degradation of carnitine palmitoyltransf	28
Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes	28
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI	28
The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus	28
Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program	28
Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real‐world evidence	28
Targeting the cholinergic anti‐inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study	28
BALLAST study: A multicentre, open‐label, randomized‐controlled, 52‐week clinical trial of the efficacy and safety of luseogliflozin in older Japanese adults with type 2	28
Insulin therapy DE ‐ intensificAtion with iGlarLixi	28
Genotype‐guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of CHANCE ‐2	28
SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial	27
Validation of the Individualized Metabolic Surgery score in predicting long‐term remission of diabetes after duodenal switch‐type procedures	27
Cross‐sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes	27
Similarities and differences in the intestinal actions of metformin and imeglimin	27
Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study	27
Molecular signatures of brain glycolysis dysfunction in Alzheimer's disease	27
Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome	27
Association of single‐point insulin sensitivity estimator index (SPISE) with future cardiovascular outcomes in patients with type 2 diabetes	27
Sick days glycaemic outcomes in a cohort of children and adolescents with type 1 diabetes using an AID system—A preliminary report	26
The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials	26
Diabetes, Obesity and Metabolism	26

Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis	26
Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial	26
Associations of metabolic syndrome with cognitive function and dementia risk: Evidence from the UK Biobank cohort	26
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis	26
Glucose‐dependent insulinotropic polypeptide counteracts diet‐induced obesity along with reduced feeding, elevated plasma leptin and activation of leptin‐responsive and proopiomelanocortin neurons in	26
Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA	26
Front Cover	26
Cannabidiol improves metabolic profiles and alleviates liver inflammation and fibrosis in conditions of androgenic obesity and polycystic ovary syndrome	26
Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials	25
S odium‐glucose co‐transporter‐2 inhibitors: Writing the next chapter of a unique success story	25
	25
Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline HbA1c ,	25
Diabetes, Obesity and Metabolism	25
Changes in remnant cholesterol and the incidence of diabetes: Results from two large prospective cohort studies	25
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis	25
Long‐term glycemic exposure, glycemic control stability and incident calcific aortic valve disease: A prospective cohort study	25
Targeting gut‐derived NETosis : A paradigm shift in understanding metformin's therapeutic action	25
Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks	25
Front Cover	25
	25
Peptidylarginine deiminase 4‐mediated neutrophil extracellular trap formation aggravates β‐cell damage in type 1 diabetes: A multi‐model study	25
Cost‐Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across	24
Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity	24
The impact of family history of type 2 diabetes on clinical heterogeneity in idiopathic type 1 diabetes	24
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase	24
Pharmacokinetic properties of insulin GZR4 after subcutaneous administration in the thigh, abdomen, or upper arm in healthy participants	24
Polarized macrophages promote gestational beta cell growth through extracellular signal‐regulated kinase 5 signalling	24
Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study	24
Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE rando	24
Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 st	24
Commonly used C‐peptide assays show differing associations with CGM metrics	24
Bone marrow metabolism is affected by body weight and response to exercise training varies according to anatomical location	24
Challenging the 50‐50 rule for the basal‐bolus insulin ratio in patients with type 2 diabetes who maintain stable glycaemic control	24
Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized do	24
Glycaemia and cardiac arrhythmias in people with type 1 diabetes: A prospective observational study	24
Safety and efficacy of hybrid closed‐loop insulin pump therapy in adolescents and adults with type 1 diabetes in China	23
The effect of sugarcane extract supplementation on glycemic control in a mouse model of type 1 diabetes	23
Optimising the CamAPS FX automated insulin delivery system for exercise and complex meals in adolescents with type 1 diabetes: A prospective interven	23
Modelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease:	23
Altered high‐density lipoprotein composition is associated with risk for complications in type 2 diabetes mellitus in South Asian descendants: A cross‐sectional, case‐control study on lipoprotein subc	23
Cost‐effectiveness of continuous glucose monitoring in Chinese adults with uncontrolled type 2 diabetes: A modelling study stratified by baseline HbA	23
Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial	23
Nasal glucagon is safe and effective in children and adolescents with type 1 diabetes: A real‐world prospective cohort study	23
Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID ‐19:	23
Medical events and costs associated with metabolic bariatric surgery among adults with type 2 diabetes: A retrospective, matched cohort study	23
Acute inflammation amplifies the diabetogenic effect of excess adiposity: Evidence from a real‐life, prospective cohort	23
Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?	23
Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials	23
Association of device measured physical activity with liver fat and stiffness in people with type 1 diabetes	22
Frequency and sequence of proteinuria positivity and clinical outcomes in patients with diabetes: A nationwide cohort study	22
Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial	22
Acidosis is associated with lower insulin sensitivity and incident type 2 diabetes in indigenous Americans: A prospective cohort study	22
The interaction effect between BMI , diabetes and age at diabetes onset on the risk of thyroid cancer: A population‐based cohort study in Shanghai, C	22
Baseline clinical factors associated with diabetes distress in dialysis patients: Insights from the ABCD audit data	22
Antidiabetic and lipid‐lowering medication use inversely linked with serum biomarkers of liver fibrosis	22
When can weekly anti‐obesity peptides be used for monthly administration?	22
Dapagliflozin modulates hepatic lipid metabolism through the proprotein convertase subtilisin/kexin type 9/low density lipoprotein receptor pathway	22
Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time‐in‐ranges in Chinese adults	22
Safety and efficacy of the therapy with CD4  +  CD25highCD127 ‐T regulatory cells: When paediatric	22
Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism	22
Association between the body mass index and risk of cardiovascular events in sodium‐glucose cotransporter 2 inhibitor users compared with	22
Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japa	22
Male–female differences in insulin sensitivity and β‐cell function in US elders with and without abdominal obesity: An exploratory study with an in‐d	22
Neural pathways to bariatric success: What explainable AI reveals that conventional fMRI methods m	22
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron ( PF ‐06882961), an oral small‐molecule gl	22
Enhancing postpartum cardiometabolic health for women with previous gestational diabetes: Next steps and unanswered questions for pharmacological and lifestyle strategies	21
Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT	21
Association of body roundness index with cardiovascular disease and all‐cause mortality among Chinese adults	21
Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT	21
Impact of time in tight range on all‐cause and cardiovascular mortality in type 2 diabetes: A prospective cohort study	21
Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabete	21
Incidence and risk factors of new‐onset diabetes mellitus: A five‐year follow‐up study in solid organ transplant recipients in Germany	21
Correction to “Efficacy and safety in tirzepatide‐treated Korean adults with type 2 diabetes—A post hoc analysis of SURPASS‐AP‐combo and SURPASS‐3”	21
Beyond Glucose: A Brain Energy Bottleneck Hypothesis for Multi‐Energy Substrates in Hypoglycaemia Rescue	21
Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched coho	21
Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials	21
Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DP	21
A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated w	21
Characterisation of steady‐state pharmacokinetics and glucodynamics of once‐weekly insulin efsitora alfa in individuals with type 2 diabetes	21
Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model	21
Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP	21
Impact of early and tight HbA1c control on the risk of long‐term complications and cardiovascular death in patients with type 2 diabetes from the Swe	21
Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐re	21
Diabetes, Obesity and Metabolism	20
Exercise‐related hypoglycaemia induces QTc ‐interval prolongation in individuals with type 1 diabetes	20
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes	20
The effects of kisspeptin on food intake in women with overweight or obesity	20
Front Cover	20
Hypoglycaemia and rebound hyperglycaemia increase left ventricular systolic function in patients with type 1 diabetes	20
Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes	20
One‐year real‐world performance of the DBLG1 closed‐loop system: Data from 3706 adult users with type 1 diabetes in Germany	20
	20
Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight	20
Fat‐to‐muscle ratio is associated with insulin resistance and cardiometabolic disorders in adults with type 1 diabetes mellitus	20
Neighbourhood‐level social deprivation and the risk of recurrent heart failure hospitalizations in type 2 diabetes	20